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Abstract
During the past few decades, the investigative tech-
nologies of molecular biology - especially sequencing - 
underwent huge advances, leading to the sequencing of 
the entire human genome, as well as the identification 
of several candidate genes and the causative genetic 
variations that are responsible for monogenic skin 
diseases. These advances provided a solid basis for 
subsequent studies elucidating mechanisms of monogenic 
skin diseases and improving our understanding of 
common skin diseases. Furthermore, these discoveries 
also contributed to the development of novel therapeutic 
modalities for monogenic skin diseases. In this review, 
we have used the disease spectrum caused by mutations 
in the CYLD  gene - Brooke-Spiegler syndrome, familial 
cylindromatosis and multiple familial trichoepithelioma 
type 1 - as a model for demonstrating the knowledge 
explosion for this group of diseases. 
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Core tip: Although dermatology is a morphology-orientated 
specialty, genetic investigation can help understand 
the events taking place in the skin of the affected 
patients. Genetic investigation of Brooke-Spiegler 
syndrome, familial cylindromatosis and multiple familial 
trichoepithelioma type 1 further supported the clinical 
hypothesis that these monogenic skin diseases are not 
different entities, but rather clinical variants of a disease 
spectrum caused by mutations in the cylindromatosis 
(CYLD ) gene. In addition to understanding the 
underlying mechanisms of these allelic variants, genetic 
investigation can also accelerate the development of 
novel therapeutic modalities, such as therapy using 
tropomyosin-receptor-kinase specific lestaurtinib for 
patients with germline CYLD mutations.
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INTRODUCTION
From ancient times to the present, the basic approach for 
diagnosing skin diseases has been to classify the diseases 
according to their visible signs and symptoms. This approach 
highlights that dermatology is still a highly morphology-
orientated specialty. The end of  the 18th century saw great 
breakthroughs in dermatology: the first comprehensive 
textbook of  modern dermatology was published in 1799 
by Francesco Bianchi[1] and the first great school of  
dermatology was established in Paris in 1801[2]. Since that 
time, the desire to understand the nature of  observed skin 
lesions constantly drives the development of  dermatology 
and the incorporation of  novel investigative methods into 
its everyday practice. 
Among these methods, dermatohistopathology has 
had the highest impact on the diagnosis of  skin diseases. 
Although the microscope was invented by Anton van 
Leeuwenhoek as early as 1673, the first standardized and 
classified nomenclature of  dyes and stains was prepared 
only in 1924[3,4]. Since that time, enzyme histochemistry, 
electron microscopy, polarizing microscopy, immune-
histochemistry and in vivo confocal microscopy have 
all become diagnostic tools in dermatohistopathology 
and have been integrated into everyday dermatology 
practices[3,4]. In recent decades, developments in the 
investigative fields of  clinical genetics and genomics have 
further accelerated our knowledge about skin diseases. 
Breeding agricultural plants and animals characterized 
the pre-Mendel era of  genetics[5,6]. After Gregor Mendel 
established the basic rules of  heredity in the nineteenth 
century[7], several major discoveries, such as the identification 
of  DNA as the material encoding inheritable information, 
of  the genetic code and of  the mechanisms of  gene 
expression, have initiated the era of  molecular genetics[8,9]. 
Very recently, the enormous technical development of  
sequencing methods and platforms has resulted in large-
scale genomic projects, which produce amounts of  data 
that were unimaginable a few decades ago[10,11]. 
These discoveries and techniques have been used 
to identify several normal genetic variations, as well as 
candidate genes and their disease-causing mutations, 
accelerating the elucidation of  the genetic background of  
several monogenic skin diseases. In this review, we present 
the knowledge explosion for monogenic skin diseases, using 
as an example the disease spectrum caused by mutations in 
the CYLD gene, which involves Brooke-Spiegler syndrome 
(BSS) (OMIM 605041), familial cylindromatosis (FC) 
(OMIM 132700) and multiple familial trichoepithelioma 
type 1 (MFT1) (OMIM 601606) (Table 1).
DISCUSSION
BSS is a rare monogenic skin disease characterized by the 
development of  a wide variety of  benign skin appendageal 
tumors, such as cylindromas, trichoepitheliomas and/or 
spiradenomas[12,13]. BSS was named after the two physicians 
who first reported these neoplasms in 1892 and 1899: 
Henry G Brooke and Eduard Spiegler, respectively[14,15]. 
FC, which was originally considered a separate rare disease, 
is characterized by the development of  cylindromas[16]. 
FC was first reported in 1842 and 1899 by Henry Ancell 
and Eduard Spiegler, respectively[15,17]. MFT1, which was 
also reported as another rare entity, is characterized by 
the development of  trichoepitheliomas[16] and was first 
reported in 1892 by Brooke[14] and Fordyce[18].
Comparing the clinical features of  these tumors, 
cylindromas are benign, skin-colored tumors usually 
present as multiple turban-like protrusions on the scalp, 
trichoepitheliomas are small, benign, skin-colored tumors, 
typically located at the center of  the face, and spiradenomas 
are purple, benign, nodular tumors, usually located on 
the trunk or limbs[19]. The histological characteristics of  
cylindromas are dermal nodules of  epithelial cells lined by 
membrane-like basement material and arranged in a “jigsaw 
puzzle” pattern, of  trichoepitheliomas are dermal nodules 
of  basaloid cells with peripheral palisades arranged in nests 
or cribriform patterns and of  spiradenomas are dermal 
nodules comprised of  large light-colored epithelial cells 
with abundant cytoplasm at the center and small darker 
epithelial cells at the periphery[20-22]. Hybrid tumors can also 
occur, such as spiradenocylindromas, which exhibit the 
characteristics of  both cylindromas and spiradenomas[23].
The candidate gene for BSS was first mapped to 
chromosome 16q12-q13 in 2000[24], and the causative CYLD 
gene and its first pathogenic mutation was identified in an 
affected German pedigree in 2002[25]. The candidate gene 
for FC was first mapped to chromosome 16q12-q13 in 
1995[26]; however, the causative CYLD gene and the first 
21 pathogenic mutations were identified as late as 2000[27]. 
It was first suggested in 1995 that MFT1 and FC may 
be caused by the dysfunction of  the same gene, since 
both type of  tumors can occur in the same patient or in 
different patients within a single family[28]. The causative 
gene for MFT1 was identified as CYLD, and the first 
pathogenic mutation was detected in an affected Turkish 
family in 2003[29]. 
These clinical variants - BSS, FC and MFT1 - were 
originally described as distinct clinical entities. However, 
due to their overlapping clinical symptoms and their 
manifestation within the same family, they are currently 
considered as part of  a phenotypic spectrum of  the same 
entity[30-32]. This hypothesis is supported by genetic evidence: 
several mutations - the c.1112C/A p.S371X, the c.2272C/
T p.R758X and the c.2806C/T p.R936X nonsense 
mutations - lead to the development of  all three clinical 
variants (Table 2)[33-42].
Presumably, this is due to the fact that the nonsense 
mutations of  the CYLD gene are in general recurrent ones 
and develop due to de novo events indicating mutational 
hotspots on the gene[35]. Patients carrying the same 
nonsense mutation from different mutational events often 
exhibit extreme phenotypic differences, which might be 
the consequences of  yet unknown genetic factors that 
modify the development of  the phenotype.
To date, a total of  99 disease-causing CYLD mutations 
have been reported worldwide (Figure 1)[43-46]. The 
majority (82%) of  CYLD mutations identified to date 
February 2, 2015|Volume 4|Issue 1|WJD|www.wjgnet.com
Nagy N et al . Knowledge explosion for monogenic skin diseases 
45
are located between exon 12 and 20. This finding has a 
significant diagnostic relevance, as mutation screening of  
the affected individuals should begin with examination of  
the exon 12-20 region. Within this region, exons 16 and 
17 contain the highest number of  mutations (16%). Now 
that, because the causative mutation can be identified 
prenatally as well as preimplantation, diagnosis can be 
offered to affected families. This information can have a 
huge impact on family planning, since the symptoms of  
all clinical variants can be very stigmatizing[35]. 
Several functional studies have been performed to 
elucidate the underlying mechanism of  the CYLD-
mutation disease spectrum. The CYLD gene encodes an 
enzyme with deubiquitinase activity, which is involved in 
the post-translational modification of  its target proteins 
by removing Lys63-linked ubiquitin chains[47]. CYLD 
interacts with several members of  the NF-ĸB signaling 
pathway, including the TRAF2, TRAF6, NEMO and 
BCL3 proteins, acting as a negative regulator[48]. Mutations 
of  the CYLD gene, in general, result in decreased activity 
of  the CYLD enzyme. The reduced activity leads to the 
hyperubiquitination of  interaction partners and influences 
several signaling pathways, such as the NF-kB pathway, 
as well as affects several biological processes, such as 
the development of  the skin appendages and tumor 
formation[34]. 
It is interesting to note that, although the CYLD protein 
is expressed in a wide range of  human tissues, the reason 
why dysfunction manifests only in skin symptoms is still 
unclear[49-51]. Moreover, patients carrying the same mutation 
from different mutational events often exhibit extreme 
differences in their clinical and histological manifestations[35]. 
These differences might be the consequences of  yet 
unknown genetic, environmental and/or lifestyle factors 
that modify the development of  the phenotype. Further 
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  Name of clinical variant Familial cylindromatosis Brooke-Spiegler syndrome Multiple familial trichoepithelioma type 1
  Clinical symptoms Cylindromas Cylindromas Trichoepitheliomas Spiradenomas Trichoepitheliomas 
  Genetic background Any type of mutation Any type of mutation Any type, but mainly missense mutations
Table 1  Classification of the clinical variants within the disease spectrum caused by CYLD mutation 
  CYLD cDNA CYLD 
protein
Detected 
in patients 
with 
Nationality Ref.
  c.1112C > A p.S371X BSS, FC, 
MFT1
American, 
African American, 
Irish, 
Dutch, Austrian, 
Czech, 
Slovak, Chinese
Bignell et al[27], 2000; 
Bowen et al[30], 2005; 
Saggar et al[32], 2008;
Linos et al[40], 2011; 
Kazakov et al[39], 2011; 
Grossmann et al[33], 
2013; 
Kacerovska et al[51], 
2013; 
Lv et al[41], 2013;
Van den 
Ouweland et al[36], 
2011 
  c.2272C > T p.R758X BSS, FC, 
MFT1
 American, 
South African, 
Austrian, 
Czech, 
Dutch, 
Chinese, 
Japanese
Bignell et al[27], 2000; 
Kazakov et al[38], 2009; 
Kazakov et al[39], 2011; 
Grossmann et al[33], 
2013; 
Oiso et al[42], 2004;
Zhang et al[37], 2006;
van den 
Ouweland et al[36], 
2011
  c.2806C > T p.R936X BSS, FC, 
MFT1
American, 
Canadian, 
Anglo-Saxon, 
Czech, 
Hungarian, 
Chinese
Bignell et al[27], 2000; 
Bowen et al[30], 2005; 
Saggar et al[32], 2008; 
Kazakov et al[38], 
2009; 
Grossmann et al[33], 
2013; 
Young et al[31], 2006; 
Nagy et al[35], 2013 
Table 2  Reported clinical variants and geographic distributions 
of the most common recurrent mutations of the CYLD gene
BSS: Brooke-Spiegler syndrome; FC: Familial cylindromatosis; MFT1: 
Multiple familial trichoepithelioma type 1.
Figure 1  CYLD gene mutations identified to date. 
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Dermatol 2014; 89: 175-176 [PMID: 24626672 DOI: 10.1590/
abd1806-4841.20142194]
16 Lee DA, Grossman ME, Schneiderman P, Celebi JT. Genetics 
of skin appendage neoplasms and related syndromes. J Med 
Genet 2005; 42: 811-819 [PMID: 16272260]
17 Ancell H. History of a remarkable case of tumours, developed 
on the head and face; accompanied with a similar disease in the 
abdomen. Med Chir Trans 1842; 25: 227-306.11 [PMID: 20895749]
18 Centurión SA, Schwartz RA, Lambert WC. Trichoepithelioma 
papulosum multiplex. J Dermatol 2000; 27: 137-143 [PMID: 
10774137]
19 Uede K, Yamamoto Y, Furukawa F. Brooke-Spiegler 
syndrome associated with cylindroma, trichoepithelioma, 
spiradenoma, and syringoma. J Dermatol 2004; 31: 32-38 
[PMID: 14739501]
20 Lian F, Cockerell CJ. Cutaneous appendage tumors: familial 
cylindromatosis and associated tumors update. Adv Dermatol 
2005; 21: 217-234 [PMID: 16350444]
21 Alsaad KO, Obaidat NA, Ghazarian D. Skin adnexal 
neoplasms--part 1: an approach to tumours of the pilosebaceous 
unit. J Clin Pathol 2007; 60: 129-144 [PMID: 16882696]
22 Obaidat NA, Alsaad KO, Ghazarian D. Skin adnexal 
neoplasms--part 2: an approach to tumours of cutaneous 
sweat glands. J Clin Pathol 2007; 60: 145-159 [PMID: 16882695]
23 Pizinger K, Michal M. Malignant cylindroma in Brooke-
Spiegler syndrome. Dermatology 2000; 201: 255-257 [PMID: 
11096200]
24 Fenske C, Banerjee P, Holden C, Carter N. Brooke-Spiegler 
syndrome locus assigned to 16q12-q13. J Invest Dermatol 2000; 
114: 1057-1058 [PMID: 10792569]
25 Poblete Gutiérrez P, Eggermann T, Höller D, Jugert FK, 
Beermann T, Grussendorf-Conen EI, Zerres K, Merk HF, 
Frank J. Phenotype diversity in familial cylindromatosis: a 
frameshift mutation in the tumor suppressor gene CYLD 
underlies different tumors of skin appendages. J Invest 
studies are needed to elucidate the putative factors that are 
responsible for the observed late onset of  the symptoms, 
for the development of  only skin manifestations and for the 
great variation in phenotypes and histological findings.
To date, no causative therapy is available for BSS. 
However, recent gene expression studies demonstrated 
that tumors with somatic CYLD mutation have impaired 
TRK signaling and treatment with a small TRK-inhibiting 
molecule, lestaurtinib, can reduce colony formation 
and proliferation of  tumor cells with somatic CYLD 
mutation[52]. These data may have huge clinical significance, 
since lestaurtinib treatment might be a novel therapeutic 
modality for patients suffering from symptoms caused by 
germline CYLD mutations. 
CONCLUSION
Although dermatology and genetics are considered 
separate disciplines, the combination of  these two fields 
has already resulted in enormous improvement in the 
understanding of  monogenic skin diseases, such as 
the skin-disease spectrum caused by mutations in the 
CYLD gene. Genetic studies have proved that BSS, FC 
and MFT1, which were originally considered different 
entities, result from mutations of  the same gene. Moreover, 
mutations of  the CYLD gene have been reported in 
patients presenting all clinical variants. Genetic screening 
and the identification of  the disease-causing mutation 
have already been of  great significance for family planning 
in prenatal and preimplantation diagnosis. Furthermore, 
molecular biological investigation demonstrated that all 
known CYLD mutations lead to decreased activity of  
the encoded CYLD deubiquitinase enzyme and, thus, 
influence several signal transduction pathways. Currently, 
only symptomatic surgical treatment is available for 
patients with BSS, FC or MFT1. Gene expression studies 
of  solid tumors carrying the CYLD mutation identified 
modifications in the TRK signaling pathway and raised 
the possibility that treatment with lestaurtinib could 
potentially be a novel therapeutic modality for patients 
with germline CYLD mutation. Future genetic studies 
could also provide a solid basis for the development of  
novel causative therapies that will be more specific and 
effective than the symptomatic treatments currently 
available for patients with the FC, BSS and MFT1 variants.
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